The FDA has approved Donanemab as a new monoclonal antibody drug for Alzheimer’s disease, a condition previously considered untreatable. These drugs work by removing amyloid plaques from the brain, a hallmark of Alzheimer’s. While these antibodies have shown promise in slowing cognitive decline in patients with mild Alzheimer’s, they also come with risks such as brain swelling and bleeding. Patients with certain genetic risk factors and cardiovascular diseases are more prone to complications. Individualized treatment plans are required, and patients must weigh the risks and benefits of these treatments carefully with the guidance of a specialized physician.
Source link
What’s The Deal With Monoclonal Antibody Therapies for Alzheimer’s?
